Posttraumatic Stress Disorder (PTSD) and Alcohol Use Disorder (AUD) often co-occur, worsening outcomes, relapse rates, and treatment response. Ketamine produces rapid and sustained PTSD symptom reduction and reduces AUD relapse. Prazosin effectively treats PTSD-related nightmares and may reduce alcohol consumption in individuals with heightened autonomic reactivity. The dual complementary...
In recent years, psychopharmacology has experienced a significant challenge, highlighting a renewed and strong scientific interest in psychedelics as breakthrough therapies for mental disorders. Psychedelics can influence cognitive and emotional processes, showing solid therapeutic potential, particularly in treatment-resistant psychiatric disorders. Amongst the most promising compounds,...
Background: While ketamine is widely used in anesthesia and pain management, its non-medical use is increasing worldwide. In France, surveillance data indicate a sharp rise in ketamine-related disorders, but comprehensive characterization of affected patients and associated complications remains limited. Aims: To examine trends on ketamine in France from 2019 to 2023, and describe severe...
People with alcohol use disorder experience alterations in consciousness from 0.8 mg/kg intravenous ketamine administration. Ketamine's effects appear to be broadly consistent across three repeated infusions. Ketamine-related reductions in alcohol consumption do not appear to be mediated by the acute psychoactive effects of ketamine.
MoleculesFebruary 4, 2026Monica Patrícia Esperança, N. N. S. Gomes, Maria Graça Campos1 citation
Substance Use Disorder (SUD) constitutes a major and persistent global public health burden, accounting for approximately 600,000 deaths annually, largely driven by opioid use. Despite substantial advances in addiction neuroscience, currently approved therapeutic strategies remain limited in efficacy, as they predominantly target isolated neurobiological processes and fail to concurrently...
Non-medical ketamine use is becoming increasingly common in the United States (US), but awareness remains limited among US healthcare providers. Here we present the case of a young woman who developed severe ketamine use disorder in the setting of an acute exacerbation of chronic post-traumatic stress disorder (PTSD). She also demonstrated symptoms concerning for two known complications of...
27.1 million adults in the United States have alcohol use disorder (AUD). However, current medications for AUD have mixed efficacy. As such, a shift in treatment approach and the development of novel pharmacotherapies for AUD is imperative. This review addresses novel insights on treating AUD through precision medicine that identifies subgroups of individuals most responsive to existing single...
Major depressive disorder and co-morbid substance use disorder represent a challenging dual diagnosis, characterized by persistent anhedonia, high relapse rates, and poor response to conventional antidepressants. The dextromethorphan-bupropion combination with synergistic glutamatergic and dopaminergic mechanisms provides a new treatment option. We present three male patients with alcohol or...
Alcohol use disorders are common and contribute significantly to the global burden of disease. The treatment of alcohol dependence includes the acute withdrawal phase and the post-acute rehabilitation phase. The primary goal of post-acute treatment is long-term abstinence, although reduction of alcohol consumption is also recognized as an intermediate goal. In addition to psychosocial and...
Things to consider: .In the intro: "The so-called magic mushrooms from which psychedelics are extracted were traditionally absorbed by South-American peoples." This is clunky and I suspect it is due to translation errors; consider changing it. .In the intro: "In 1998, Dr. Heffter nally discovered a psychedelic active substance and named it mescaline." This was rst published in 1897, not 1998....
Quality in SportJanuary 26, 2026Adam Wolski, Ewa Szplit, Mikołaj Franciszek Patalong et al.
Background: Psychedelic substances have been used for millennia in religious and healing contexts and have recently re-emerged as subjects of scientific interest due to advances in neuroscience and psychiatry. Research suggests that psychedelics may address limitations of conventional psychiatric treatments, particularly in disorders such as major depressive disorder, PTSD, substance use...
The escalating global burden of mental health disorders, coupled with the stagnation of innovation in traditional monoaminergic pharmacotherapy (e.g., SSRIs), has precipitated a critical need for novel therapeutic paradigms. This article presents a comprehensive systematic review of the so-called "Psychedelic Renaissance," focusing on the clinical resurgence of classical serotonergic...
Responders were distinguished by narratives of inner dialogue and adaptive coping, while non-responders emphasized sensory and affective descriptions and suppressive coping. Inner dialogue may constitute a distinct therapeutic mechanism, highlighting the importance of preparation and integration in psilocybin-assisted psychotherapy.
CNS DrugsJanuary 17, 2026Gaëlle Rached, Anna Campana, Dimitri Fiani et al.1 citation
Monoamine oxidase inhibitors (MAOIs) remain an important option for patients with treatment-resistant depression (TRD) and other psychiatric conditions, despite potentially serious drug-drug interactions and associated dietary tyramine restrictions. However, they are rarely prescribed in patients with comorbid substance use disorders (SUDs) due to concerns about potential drug interactions and...
The psychedelic substance, ibogaine, has garnered growing interest among policymakers, researchers, and the public in its potential use for opioid use disorder (OUD). Many states are allocating significant funds to investigate it further. However, some proponents of ibogaine are framing it in opposition to (versus complementary to) standard, mortality-reducing medications for OUD (MOUD)....
Substance use disorders (SUDs) are often associated with patients' experiencing cravings, risk of relapse and poorsleep quality, all of which significantly affect their chance of recovery. In the present research, a systematic review has been used to evaluate the effectiveness of mindfulness-based interventions (MBIs) in reducing substance cravings and improving sleep quality among clients with...
Abstract This article examines the role of bodily and emotional processes in shaping consciousness and rational thought, drawing on Antonio Damasio’s work and its subsequent developments. Rejecting the traditional mind-body split, it is argued that human rationality is grounded in the biological processes that sustain it, which raises significant limitations for the feasibility of replicating...
The aim of this perspective article is to evaluate the potential of Psychedelics in the management of Alcohol Use Disorder (AUD) vis-a-vis pre-existing therapeutic modalities and to elucidate practical directions for policy in AUD Addiction medicine, supported by scientific evidence, while prioritizing safety and accessibility. We performed a narrative synthesis of past and current literature...
Open Mind2026Amin Nazmuddin Mohammadi, Christine Wekerle
preprint
Alcohol use disorder (AUD) is a prevalent and chronic psychiatric condition characterized by impaired control over alcohol use, compulsive consumption, and high rates of relapse (Grant et al., 2015; Kurihara, 2023). Despite the availability of pharmacological and psychosocial interventions, treatment outcomes remain suboptimal, with substantial rates of non-response and relapse (Lohoff, 2022;...